Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

Advisory group guidance enables nonprofit to be at the forefront of Alzheimer's research WELLESLEY HILLS, MA / ACCESSWIRE / ...

Around 20% of Allegheny County’s population is 65 and older, according to recent studies, placing among the highest ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...

The Tennessee Lady Volunteers are set to host its annual “We Back Pat” game at Food City Center on Thursday against ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

For many years, platinum-based chemotherapy has been one of the mainstays for advanced testicular cancer. Painful peripheral ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...